| Our population-based study shows that HbA1c screening in adults aged 40–70 years can reduce the time to diabetes diagnosis by a median of 2.2 years compared with routine clinical care (Diabetologia)
The predictive model achieved moderate discrimination but good calibration in a German/Austrian T2D population suggesting that the model may be relevant for determining CKD risk (Diabetes, Obesity and Metabolism)
Overall, patients with diabetes should be carefully examined in terms of CV risk stratification (e.g., taking into consideration TOD, renal function, subclinical atherosclerosis, etc.), to define their lipid goals. We strongly suggest that, for such high-risk patients, LDL-C target should be achieved as early as possible to maximize CVD prevention (Cardiovascular Diabetology)
Oral insulin (ORMD-0801) induced greater reductions in HbA1c when compared to placebo and was safe and well-tolerated in individuals with uncontrolled T2DM (Institute of Endocrinology, Metabolism & Hypertension )
People coded with remission of type 2 diabetes were less likely to receive diabetes care processes than those without such coding (Diabetic Medicine)
An intensive SBP lowering target of 110 to <130 mmHg reduces the cardiovascular outcomes compared with a standard SBP lowering target of 130 to <150 mmHg. The findings of this study support the favorable effects of intensive SBP lowering in hypertensive patients with diabetes (Diabetes, Obesity and Metabolism)
In T2D uncontrolled by basal insulin, intensification with semaglutide 1.0 mg OW was associated with better glycaemic control, weight loss, and reduced hypoglycaemia versus a basal–bolus regimen, while limiting the treatment burden associated with frequent injections. Clinicians could consider treatment intensification with semaglutide when T2D is uncontrolled by basal insulin, especially when weight management is a priority (Diabetes Therapy)
To the best of our knowledge, this is the first report on using the PDCA cycle to manage and control glucose levels in critically ill patients (Diabetes Therapy)
The European Medicines Agency therefore decided that Mounjaro’s benefits are greater than its risks and it can be authorised for use in the EU
| 